Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

Inclusion Criteria: * Patients diagnosed with multiple myeloma based on standard diagnostic criteria or by the new International Myeloma Foundation 2003 Diagnostic Criteria * Subjects must have symptomatic myeloma or asymptomatic myeloma with myeloma-related organ damage * Subjects must have measurable disease requiring systemic therapy. * Male or female subject 18 years of age or older * Karnofsky Performance Status score of ≥50% (Eastern Cooperative Oncology Group Performance Status score ≤2) * Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to therapy. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (1 highly effective method and 1 additional effective method) used at the same time, beginning at least 4 weeks before initiation of Revlimid treatment. Women must also agree to ongoing pregnancy testing * Men must agree to not father a child and agree to use a latex condom during therapy and for 4 weeks after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential. Exclusion Criteria: * Subjects must not have been treated previously wit…